In reflecting upon an array of unmet needs regarding exudative (wet) age-related macular degeneration (AMD), Sunir Garg, MD, identifies easing the treatment burden of the disease as a short-term goal. Dr Garg then details the often onerous practicalities involved in maintaining regular and consistent therapeutic schedules within a largely older patient population.
Dr Garg then turns to recent pharmacologic innovations, such as anti-VEGF combined with ANG-2, implantable reservoirs, and gene therapy, that together present the promise of easing the treatment burden by cutting down on the need for injections and office visits.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Promise of Meeting the Needs - Medscape - May 02, 2022.